Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
6.03
0.00 (0.00%)
At close: Dec 31, 2025, 4:00 PM EST
5.85
-0.18 (-2.99%)
Pre-market: Jan 2, 2026, 8:04 AM EST
Savara Employees
Savara had 59 employees as of December 31, 2024. The number of employees increased by 22 or 59.46% compared to the previous year.
Employees
59
Change (1Y)
22
Growth (1Y)
59.46%
Revenue / Employee
n/a
Profits / Employee
-$1,960,085
Market Cap
1.46B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59 | 22 | 59.46% |
| Dec 31, 2023 | 37 | 9 | 32.14% |
| Dec 31, 2022 | 28 | 6 | 27.27% |
| Dec 31, 2021 | 22 | -5 | -18.52% |
| Dec 31, 2020 | 27 | -13 | -32.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SVRA News
- 11 days ago - Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 16 days ago - Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 22 days ago - Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* - Business Wire
- 4 weeks ago - Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System - Business Wire
- 6 weeks ago - Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
- 6 weeks ago - Savara: A High-Risk Opportunity - Seeking Alpha
- 7 weeks ago - Savara Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA - GlobeNewsWire